CD19-CAR engineered NK-92 cells are sufficient to overcome NK cell resistance in B-cell malignancies.
about
Natural Killer Cells for Therapy of LeukemiaImmunological and Translational Aspects of NK Cell-Based Antitumor ImmunotherapiesChimeric Antigen Receptor-Engineered NK-92 Cells: An Off-the-Shelf Cellular Therapeutic for Targeted Elimination of Cancer Cells and Induction of Protective Antitumor ImmunityRole of Natural Killer Cells in HIV-Associated Malignancies.Preclinical targeting of aggressive T-cell malignancies using anti-CD5 chimeric antigen receptor.What Fuels Natural Killers? Metabolism and NK Cell ResponsesEngineering Natural Killer Cells for Cancer Immunotherapy.The Molecular Mechanism of Natural Killer Cells Function and Its Importance in Cancer Immunotherapy.Regulation of mTOR, Metabolic Fitness, and Effector Functions by Cytokines in Natural Killer Cells.Leveraging natural killer cells for cancer immunotherapy.Cancer Immunotherapy Using CAR-T Cells: From the Research Bench to the Assembly Line.Human Pluripotent Stem Cells to Produce Cell-based Cancer Immunotherapy.Next-Generation Chimeric Antigen Receptor T-Cell Therapy: Going off the Shelf.Chimeric antigen receptor T-cell therapy - assessment and management of toxicities.Chimeric antigen receptor (CAR)-transduced natural killer cells in tumor immunotherapy.Clinical grade manufacturing of genetically modified, CAR-expressing NK-92 cells for the treatment of ErbB2-positive malignancies.NK-92 cell, another ideal carrier for chimeric antigen receptor.Development of chimeric antigen receptors targeting T-cell malignancies using two structurally different anti-CD5 antigen binding domains in NK and CRISPR-edited T cell lines.Chimeric Antigen Receptor Expressing Natural Killer Cells for the Immunotherapy of Cancer.Tumor immunotherapy: New aspects of natural killer cells.Natural Killer Cells in Liver Disease and Hepatocellular Carcinoma and the NK Cell-Based Immunotherapy
P2860
Q26745906-DFBA436B-02E1-4FF1-994D-B2AE9589FAC6Q28079180-507B011B-7AAE-465A-BD09-A24869584E87Q33700795-EEB2FE9F-7159-4D53-8085-05C53417488DQ37712593-79941380-B832-4F0A-A2C5-97A2E1AAF048Q38722015-A8A14FC5-982F-4E69-8916-EFE9740074E4Q39249602-F40DB40C-690B-46FE-BE44-0B94BD227451Q39408704-BC268FC5-FB00-45AB-BBA4-FC4A3C39C1BCQ41684097-1989A3A5-5BA7-495D-8A61-998D44395F28Q43166710-22579384-0C52-4F6A-9ABE-1CC31D02207CQ43865719-BDA68F01-6D05-41D9-837D-BD662AC35BB6Q45872592-D8373A11-D29D-47F2-B5F9-CD12854693F0Q46350666-025C36C3-6FBE-4E89-858B-128A943244C9Q47215994-C58BD01B-5D47-4C5F-94AC-696211CCCF2CQ47681829-565051F0-52B9-4112-9E7B-62CAEB575855Q47843897-CAAAAA14-62D7-4D6D-9A75-7E9726F259C1Q50027343-8B855E53-DDB0-486D-96F5-CFFC6CD7FECEQ50027824-211FA2C8-7E08-4739-A78C-28B78BCFA367Q52430204-A7EC1E20-FB5B-44AF-9F35-EE980C03DA70Q53705286-9B9C2500-B243-4DAF-9A7A-F7554A468F56Q55107050-B9CF885D-F286-4458-B902-99024D764E8AQ58764532-4921F058-A624-44CB-A1C3-C74E1C394772
P2860
CD19-CAR engineered NK-92 cells are sufficient to overcome NK cell resistance in B-cell malignancies.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
2016年论文
@zh
2016年论文
@zh-cn
name
CD19-CAR engineered NK-92 cell ...... stance in B-cell malignancies.
@en
type
label
CD19-CAR engineered NK-92 cell ...... stance in B-cell malignancies.
@en
prefLabel
CD19-CAR engineered NK-92 cell ...... stance in B-cell malignancies.
@en
P2093
P2860
P356
P1476
CD19-CAR engineered NK-92 cell ...... stance in B-cell malignancies.
@en
P2093
Annette Romanski
Christoph Uherek
Erhard Seifried
Gesine Bug
Hans Klingemann
Oliver G Ottmann
Torsten Tonn
Winfried S Wels
P2860
P304
P356
10.1111/JCMM.12810
P577
2016-03-23T00:00:00Z